Selank 10 mg

Selank Peptide for Sale: Research-Grade Tuftsin-Derived Anxiolytic

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the endogenous immunomodulatory peptide tuftsin. Researchers studying GABAergic modulation, stress-response pathways, or non-sedating anxiolytic mechanisms need a reliable domestic source for this compound. Pure Peptide Factory supplies research-grade selank peptide in 5mg and 10mg lyophilized vials with full batch documentation and cold-chain integrity. Developed by the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank is stabilized with a C-terminal Pro-Gly-Pro tripeptide extension that confers resistance to proteolytic degradation while preserving the core tuftsin activity responsible for its anxiolytic and immunomodulatory effects (1).

Unlike classical anxiolytics such as benzodiazepines, Selank does not produce sedation, muscle relaxation, or cognitive impairment. Its mechanism involves allosteric modulation of GABA_A receptors at non-benzodiazepine binding sites, enhancement of endogenous enkephalin activity through enkephalinase inhibition, and regulation of monoamine neurotransmitter systems including serotonin and norepinephrine. Consequently, researchers who purchase selank peptide for stress-response studies work with a compound that dissociates anxiolytic activity from the motor and cognitive side effects that confound benzodiazepine research. Furthermore, Selank was registered as a pharmaceutical drug in Russia in 2009 (“Selank 0.15%” nasal drops) for generalized anxiety disorder and neurasthenia, providing researchers with published human clinical data that most research peptides lack entirely (2).

Why Researchers Buy Selank Peptide from Pure Peptide Factory

Documentation for a Defined Synthetic Heptapeptide

Selank is a precisely sequenced heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) with a molecular formula of C₃₃H₅₇N₁₁O₉ and a molecular weight of 751.9 g/mol. The C-terminal Pro-Gly-Pro motif is the structural feature that confers resistance to proteolytic degradation, and incomplete or incorrect C-terminal amidation will produce a compound with significantly shorter plasma stability. Every batch we ship includes lot-specific HPLC and mass spectrometry documentation verifying purity (99.2% on current batch #PPF-SLK-0513) and sequence integrity. The Certificate of Analysis is downloadable before your compound ships. Therefore, researchers who purchase selank peptide from our facility can trust the Pro-Gly-Pro stabilization motif is intact before beginning any GABAergic or stress-response protocol.

Two SKU Configurations for Protocol Flexibility

We stock selank peptide in 5mg and 10mg lyophilized vials. The 5mg configuration accommodates pilot studies, dose-finding protocols, and acute GABAergic modulation experiments. The 10mg format supports extended chronic stress models where 0.3 mg/kg/day is administered intraperitoneally for 14 to 28 days, matching the published Kozlovskaya et al. (2003) protocol. Consequently, researchers can match vial size to protocol duration without splitting vials or compromising sterile handling. For reconstitution, researchers typically pair Selank with our bacteriostatic water, also stocked domestically under identical cold-chain conditions.

Domestic Cold-Chain Integrity

This synthetic heptapeptide remains stable as lyophilized powder but degrades with moisture exposure and temperature excursion after reconstitution. We store all selank peptide inventory under domestic cold-storage conditions at -20°C and ship using phase-change cooling rated for 96-hour protection. Most orders arrive within 1 to 3 business days, protecting peptide integrity from warehouse to laboratory bench.

Compare Against Complementary Nootropic Peptides Without Batch Variables

Many research protocols compare Selank against other nootropic and neurotrophic compounds such as Semax (ACTH-derived cognitive enhancer), Cerebrolysin (porcine neurotrophic complex), or P21 (CNTF-derived tetrapeptide). Because we stock the full nootropic peptide panel under identical cold-storage conditions, researchers who source selank peptide alongside these complementary compounds eliminate supplier variability from their cross-compound data.

Synthesis Logs Archived for 24 Months

Should your IRB or compliance office request chain-of-custody records, we provide them without delay.

What Is Selank Peptide?

A Tuftsin-Derived Heptapeptide with Enhanced Stability

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed in Russia as a stable analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) with immunomodulatory and neuromodulatory properties. The addition of the Pro-Gly-Pro (PGP) tripeptide at the C-terminus dramatically extends metabolic stability while preserving the core tuftsin activity responsible for anxiolytic and immunomodulatory effects. Kozlovskaya et al. (2003) demonstrated that selank peptide exhibits anxiolytic effects in rodent models of unpredictable chronic mild stress, with activity comparable to diazepam but without the sedative side-effect profile (1).

Russian Pharmaceutical Registration and Clinical Data

Selank was registered as a pharmaceutical drug in Russia in 2009 (“Selank 0.15%” nasal drops) for the treatment of generalized anxiety disorder and neurasthenia. Uchakina et al. (2008) conducted a randomized controlled trial in 62 patients with generalized anxiety disorder, finding that Selank 0.15% nasal drops produced anxiolytic effects comparable to medazepam (a benzodiazepine) but with superior tolerability and no sedation. Patients also reported improved emotional stability and reduced fatigue (2). This clinical data provides researchers with a human safety and efficacy reference framework. However, Selank has not undergone FDA review and is not approved for any indication in the United States or European Union.

Molecular Profile:

• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)
• Molecular Formula: C₃₃H₅₇N₁₁O₉
• Molecular Weight: 751.9 g/mol
• CAS Number: 129954-34-3
• Classification: Synthetic tuftsin-derived heptapeptide
• Stabilization Motif: C-terminal Pro-Gly-Pro extension
• Half-Life: Approximately 2 minutes in plasma; rapid blood-brain barrier penetration; biological effects persist several hours
• Synonyms: Selank, Selanc, TP-7, Tuftsin analog
• Developer: Institute of Molecular Genetics, Russian Academy of Sciences
• Clinical Status: Registered in Russia (2009) for anxiety and neurasthenia; not FDA approved

How Selank Peptide Works: Multi-Target GABAergic and Neuroplastic Modulation

Selank operates through multiple converging mechanisms that distinguish it from single-target anxiolytics:

First, allosteric modulation of GABA_A receptors. Selank binds to GABA_A receptors at sites distinct from the benzodiazepine recognition site, enhancing chloride channel conductance without producing the sedation, muscle relaxation, or dependence associated with classical benzodiazepines. This non-benzodiazepine binding profile is the structural basis for Selank’s unique ability to provide anxiolysis without motor impairment (1).

Second, enkephalinase inhibition. Selank inhibits the enzymes that degrade endogenous enkephalins, extending the half-life of these natural opioid peptides involved in stress adaptation, emotional regulation, and pain modulation. This mechanism contributes to both the anxiolytic and mood-stabilizing effects observed in preclinical models.

Third, monoamine system normalization. Selank normalizes norepinephrine and serotonin turnover in stress-responsive brain regions (hippocampus, hypothalamus, amygdala) without causing the global monoamine depletion seen with chronic stress. This restorative rather than disruptive profile on neurotransmitter systems is a key differentiator from reuptake inhibitors that simply increase synaptic neurotransmitter levels.

Fourth, BDNF upregulation. Kozlovskaya et al. (2009) demonstrated that selank peptide increases brain-derived neurotrophic factor (BDNF) mRNA expression in the hippocampus, supporting synaptic plasticity and neurogenesis. These neuroplastic changes require 7 to 14 days of chronic administration to fully manifest and likely underlie the peptide’s long-term anxiolytic and nootropic effects (3).

Selank Peptide Benefits in Research

The documented benefits of selank peptide in preclinical and clinical research include:

• GABAergic Modulation Without Sedation: Selank allosterically modulates GABA_A receptors at non-benzodiazepine binding sites, producing anxiolytic effects without the drowsiness, motor impairment, or dependence liability of classical GABAergic drugs.
• Enkephalinase Inhibition: Selank inhibits the degradation of endogenous enkephalins, extending the half-life of these natural opioid peptides involved in stress adaptation and emotional regulation.
• Monoamine System Regulation: Selank normalizes norepinephrine and serotonin turnover in stress-responsive brain regions without causing global monoamine depletion.
• BDNF Upregulation: Selank increases BDNF mRNA expression in the hippocampus, supporting synaptic plasticity and neurogenesis, mechanisms that may underlie its long-term anxiolytic and nootropic effects (3).
• Immunomodulatory Activity: As a tuftsin derivative, Selank retains immunomodulatory properties, including cytokine profile regulation and modulation of T-helper cell differentiation.
• Stress-Induced Memory Protection: Selank prevents stress-induced impairment of memory consolidation and retrieval in animal models, distinguishing it from anxiolytics that impair cognitive function (4).

Selank vs Semax: Understanding the Critical Distinction

Selank and Semax are frequently discussed together as Russian-developed nootropic peptides, but they differ fundamentally in structure, mechanism, and primary research applications. Understanding this distinction is essential for correct experimental design when comparing semax vs selank:

Feature	Selank	Semax
Parent Molecule	Tuftsin (immunomodulatory tetrapeptide)	ACTH(4-10) fragment (adrenocorticotropic hormone)
Sequence	Thr-Lys-Pro-Arg-Pro-Gly-Pro	Met-Glu-His-Phe-Pro-Gly-Pro
Primary Mechanism	GABA_A allosteric modulation; enkephalinase inhibition	BDNF/NGF upregulation; melanocortin receptor modulation
Primary Effect	Anxiolytic, stress-reducing, emotional stabilization	Cognitive enhancement, neuroprotection, focus
Sedation	None (non-sedating anxiolytic)	None (mildly stimulating)
Neurotransmitter Focus	GABA, enkephalins, serotonin, norepinephrine	Dopamine, BDNF, TrkB, VEGF
Immunomodulation	Strong (tuftsin-derived)	Moderate (anti-inflammatory gene effects)
Clinical Registration	Russia (2009) for anxiety, neurasthenia	Russia for stroke, cognitive disorders
Research Use Case	Anxiety models, stress resilience, GABA pharmacology	Stroke recovery, cognitive enhancement, BDNF studies

For laboratories studying the intersection of anxiety and cognition, selank peptide and Semax may serve as complementary tools in parallel experimental arms. Selank addresses the emotional and stress component; Semax addresses the cognitive and neurotrophic component. They are not interchangeable and should not be treated as mechanistically redundant. Both compounds are available from our catalog under identical cold-storage conditions for clean comparison data.

Selank Dosage Reference for Preclinical Research

For laboratory protocols only. We do not provide human dosing recommendations.

Model	Dose	Route	Frequency	Duration	Key Finding
Rodent anxiolytic (chronic mild stress)	0.3 mg/kg	Intraperitoneal	Once daily	14 to 28 days	Anxiolytic effect comparable to diazepam without sedation (1)
Rodent memory protection	0.3 to 1.0 mg/kg	Intraperitoneal or Subcutaneous	Once daily	7 to 14 days	Prevented stress-induced memory impairment (4)
Intranasal (rodent)	0.01 to 0.05 mg/kg	Intranasal instillation	Once daily	14 to 28 days	Direct nose-to-brain delivery; lower systemic exposure
In vitro neuronal culture	10 to 100 µM	Cell culture media	Continuous	24 to 72 hours	BDNF mRNA upregulation; GABA_A subunit expression changes

Selank exhibits rapid onset of anxiolytic effects (within 30 to 60 minutes in rodent models) but requires 7 to 14 days of chronic administration for full expression of BDNF-mediated neuroplastic changes. Acute dosing studies capture GABAergic modulation; chronic protocols capture structural neuroplasticity. Consequently, researchers who purchase selank peptide should align dosing duration with the specific mechanism under investigation. The 5mg and 10mg vial configurations support all the dose levels listed above.

How to Reconstitute Selank Peptide

Step-by-Step Laboratory Protocol

1. Sanitize the vial stopper with 70% isopropyl alcohol.
2. Using our bacteriostatic water (0.9% benzyl alcohol), inject the sterile diluent slowly against the vial wall. Allow diluent to trickle down; do not force-stream directly at the lyophilized cake.
3. Allow the powder to dissolve without agitation for 1 to 2 minutes. The heptapeptide is highly soluble in aqueous solution.
4. Gently swirl until the solution is completely clear. Do NOT shake or vortex.
5. Inspect for clarity. Discard if turbid or containing particulate matter.
6. Label with date, concentration, and store as directed below.

Concentration Reference for 10mg Vial

Diluent Volume	Concentration	0.1 mL Aliquot	Common Research Use
5.0 mL	2.0 mg/mL	0.2 mg (200 mcg)	Standard in vivo dosing
10.0 mL	1.0 mg/mL	0.1 mg (100 mcg)	Dose-finding and titration
2.0 mL	5.0 mg/mL	0.5 mg (500 mcg)	High-concentration studies

Storage Requirements

• Lyophilized powder: 24 months at -20°C, protected from light and moisture.
• Reconstituted solution: 14 to 28 days at 2 to 8°C. Avoid repeated freeze-thaw cycles.
• The Pro-Gly-Pro stabilization motif provides some protection against proteolysis, but standard peptide storage practices should still be followed.

Selank Side Effects in Research Models

Preclinical and clinical data indicate a favorable safety profile for selank peptide. Key observations include:

• No Sedation or Motor Impairment: Unlike benzodiazepines, Selank does not produce ataxia, muscle relaxation, or cognitive slowing in animal models or human studies.
• No Dependence or Withdrawal: Chronic administration studies in rodents showed no signs of physical dependence, tolerance, or rebound anxiety upon discontinuation.
• Local Irritation (Intranasal): Mild nasal dryness or irritation may occur with intranasal administration, particularly at higher concentrations or with frequent dosing.
• Headache: Rarely reported in clinical studies; typically mild and self-limiting.
• Allergic Reactions: As with any peptide, hypersensitivity reactions are theoretically possible, though no significant immunogenicity has been documented in the published literature.
• Unknown Long-Term Effects: While short-term safety data are robust, multi-year chronic administration studies have not been published.

Product Specifications

Available Configurations

Selank peptide is available in 5mg and 10mg lyophilized powder vials. Select your configuration from the product options above.

Quality Verification

• Purity: 99.2% by RP-HPLC (current batch #PPF-SLK-0513)
• Identity: Confirmed by MALDI-TOF mass spectrometry against monoisotopic mass 751.9 Da
• Endotoxin: Less than 0.05 EU/µg by LAL assay
• Sterility: Verified per USP 71
• Form: Lyophilized powder
• Storage: -20°C long-term, 2 to 8°C after reconstitution
• CAS Number: 129954-34-3

Current Batch: #PPF-SLK-0513
Purity: 99.2%
Download: HPLC Certificate | Mass Spec Report

Frequently Asked Questions

What is Selank peptide used for in research?

Researchers use selank peptide to study GABAergic modulation, stress-response pathways, non-sedating anxiolytic mechanisms, enkephalinase inhibition, BDNF upregulation, and immunomodulation. It is particularly valuable for research into anxiolytics that do not produce sedation or cognitive impairment.

How does Selank work?

Selank operates through multiple mechanisms: allosteric modulation of GABA_A receptors without benzodiazepine-site binding, inhibition of enkephalin-degrading enzymes extending endogenous opioid peptide activity, normalization of monoamine turnover (serotonin, norepinephrine) in stress-responsive brain regions, and upregulation of BDNF mRNA in the hippocampus.

How does Selank compare to Semax?

Selank is a tuftsin-derived anxiolytic focused on GABAergic and stress pathways. Semax is an ACTH-derived nootropic focused on cognitive enhancement and BDNF/TrkB signaling. Selank reduces anxiety without sedation; Semax enhances focus and neuroprotection. They are complementary, not interchangeable. See the full comparison table above.

What is the Selank half-life in research?

Selank has a plasma half-life of approximately 2 minutes due to rapid enzymatic degradation. However, its biological effects persist for several hours because the compound crosses the blood-brain barrier quickly and exerts sustained receptor-level changes (GABA_A subunit expression, enkephalin stabilization, BDNF transcription) that outlast its plasma presence.

How long does Selank take to work in research models?

Acute anxiolytic effects are observable within 30 to 60 minutes in rodent models. BDNF-mediated neuroplastic changes require 7 to 14 days of chronic administration. Researchers should align observation windows with the specific mechanism under investigation.

What are Selank side effects in research models?

Preclinical and clinical data show no sedation, motor impairment, dependence, or withdrawal. Mild nasal dryness may occur with intranasal administration. Headache is rarely reported. No significant immunogenicity has been documented.

Where can I buy Selank peptide for research?

Pure Peptide Factory supplies research-grade selank peptide domestically in 5mg and 10mg vials with same-day cold-chain shipping. Orders placed before 2 PM EST ship same-day and most arrive within 1 to 3 business days with full HPLC and mass spectrometry documentation.

Is Selank FDA approved?

No. Selank is registered as a pharmaceutical in Russia (2009) for anxiety and neurasthenia, but it has not undergone FDA review and is not approved for any indication in the United States. Research-grade Selank is for laboratory use only.

How should I store Selank peptide after reconstitution?

Store reconstituted solution at 2 to 8°C and use within 14 to 28 days. Avoid repeated freeze-thaw cycles. Reconstitute using our bacteriostatic water for optimal sterility and stability.

Can Selank be combined with other nootropic peptides in research?

Yes. Many researchers compare Selank with Semax for parallel anxiolytic versus cognitive enhancement studies. Combination protocols with Cerebrolysin or P21 are used to study multi-pathway neurotrophic and stress-resilience mechanisms. All compounds are available from our catalog under identical storage conditions.

Buy Selank Peptide for Your Research

Secure Checkout

• Credit card, cryptocurrency, or wire transfer
• Same-day dispatch for orders placed before 2 PM EST
• Cold-chain packaging with phase-change cooling
• Discreet labeling and full tracking

Institutional Accounts

Net-30 terms and purchase orders accepted for universities and research institutions. Contact us for bulk pricing on 50 vials or more, including matched orders alongside Semax, Cerebrolysin, P21, and bacteriostatic water for comprehensive neuroscience and stress-resilience research protocols.

Add to cart and get batch-verified Selank peptide delivered with the documentation your GABAergic pharmacology, stress-response, or anxiolytic mechanism research requires.